<DOC>
	<DOCNO>NCT00621452</DOCNO>
	<brief_summary>This phase I trial study side effect give genetically engineer lymphocytes together cyclophosphamide aldesleukin treat patient relapsed refractory mantle cell lymphoma indolent B-cell non-Hodgkin lymphoma . Placing gene create laboratory white blood cell may make body build immune response kill cancer cell . Drugs use chemotherapy , cyclophosphamide , work different way stop growth cancer cell , either kill cell stop dividing . Aldesleukin may stimulate white blood cell kill lymphoma cell . Giving genetically engineer lymphocytes together cyclophosphamide aldesleukin may effective treatment mantle cell lymphoma B-cell non-Hodgkin lymphoma</brief_summary>
	<brief_title>Genetically Engineered Lymphocytes , Cyclophosphamide , Aldesleukin Treating Patients With Relapsed Refractory Mantle Cell Lymphoma Indolent B-Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess feasibility , safety toxicity cellular immunotherapy utilize ex-vivo expand autologous T cell genetically modify express `` second generation ' cluster differentiation ( CD ) 20-specific scFvFc : CD28 : CD137 : zeda chimeric immunoreceptor patient recurrent refractory CD20+ mantle cell indolent lymphoma . SECONDARY OBJECTIVES : I . To determine duration vivo persistence adoptively transfer CD20-specific T cell transfected CD20-specific scFvFc : CD28 : CD137 : zeda chimeric immunoreceptor . II . To assess traffic CD20-specific T cell lymphoma mass . III . To evaluate development host anti-CD20 scFvFc : CD28 : CD137 : zeda chimeric immunoreceptor anti-neomycin-resistance gene ( NeoR ) immune response study subject . OUTLINE : CHEMOTHERAPY : Patients receive cyclophosphamide IV 60 minute . IMMUNOTHERAPY : Beginning 2 day completion cyclophosphamide , patient receive autologous CD20-specific T-cells IV 30 minute . Treatment repeat every 2-5 day 3 course . MAINTENANCE THERAPY : Beginning 2 hour last T-cell infusion , patient receive low-dose aldesleukin subcutaneously twice daily 14 day . Treatment continue absence disease progression unacceptable toxicity . Subjects achieve least partial remission last minimum 6 month may , case-by-case basis , receive additional store T cell follow relapse . After completion study treatment , patient follow weekly one month , monthly 1 year , annually 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Male female subject immuno histopathologically document CD20+ mantle cell lymphoma , follicular nonHodgkin lymphoma ( NHL ) , small lymphocytic lymphoma/chronic lymphocytic leukemia , marginal zone , lymphoplasmacytic NHL age , gender , ethnic group relapse refractory conventional chemotherapy eligible Fred Hutchinson Cancer Research Center ( FHCRC ) /University Washington Medical Center ( UWMC ) transplant protocol ( refuse participation transplant protocol ) Willingness sign inform consent undergo study test Willingness receive cytoreductive chemotherapy , necessary debulk tumor prior T cell administration , receive cyclophosphamide lymphodepletion Serologic evidence prior exposure EpsteinBarr virus ( EBV ) Meets safety criterion undergo leukapheresis Hemoglobin &gt; 9.0 gm/dL White blood cell ( WBC ) &gt; 2500 per microliter Alanine aminotransferase ( ALT ) ( serum glutamic pyruvate transaminase [ SGPT ] ) = &lt; 2.5 x Upper Limit Normal Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) = &lt; 2.5 x Upper Limit Normal Creatinine = &lt; 1.6 mg/dL Willingness use acceptable ( barrier hormonal method ) birth control appropriate course study Treatment fludarabine cladribine within previous 2 year prior apheresis Known central nervous system involvement NHL Pulmonary involvement NHL ; diagnosis pulmonary lymphoma base part finding chest compute tomography ( CT ) , clinically appropriate , lung biopsy Exposure chemotherapeutic agent ( standard experimental ) immunosuppressive therapy less four week prior apheresis ; patient must recover acute side effect therapy Positive serology human immunodeficiency virus ( HIV ) Active Hepatitis B Hepatitis C infection History hypersensitivity reaction murine proteins seropositivity human antimouse antibody ( HAMA ) Requirement corticosteroid therapy study period unless use specifically amelioration toxicity induce transferred cell Treatment antiCD20 antibody ( rituximab , tositumomab , ibritumomab ) within 4 month prior start T cell infusion Patients lymph node excess 5 cm diameter time T cell infusion Patients &gt; 5000 circulate CD20+ lymphocytes per mm^3 time T cell infusion Previous allogeneic stem cell transplantation Life expectancy le 90 day Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>